Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar;24(12):1900170.
doi: 10.2807/1560-7917.ES.2019.24.12.1900170.

Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019

Emi Takashita  1 , Chiharu Kawakami  2 , Rie Ogawa  1 , Hiroko Morita  1 , Seiichiro Fujisaki  1 , Masayuki Shirakura  1 , Hideka Miura  1 , Kazuya Nakamura  1 , Noriko Kishida  1 , Tomoko Kuwahara  1 , Akira Ota  3 , Hayato Togashi  3 , Ayako Saito  4 , Keiko Mitamura  5 , Takashi Abe  6 , Masataka Ichikawa  7 , Masahiko Yamazaki  8 , Shinji Watanabe  1 , Takato Odagiri  1
Affiliations

Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019

Emi Takashita et al. Euro Surveill. 2019 Mar.

Abstract

In January 2019, two influenza A(H3N2) viruses carrying an I38T substitution in the polymerase acidic subunit (PA), which confers reduced susceptibility to baloxavir, were detected from epidemiologically unrelated hospitalised children in Japan. The viruses exhibited reduced susceptibility to baloxavir but were susceptible to neuraminidase inhibitors. Only one of the two children had been treated with baloxavir. An epidemiological analysis suggests possible transmission of the PA I38T mutant A(H3N2) virus among humans.

Keywords: Influenza virus; baloxavir acid; baloxavir marboxil; cap-dependent endonuclease inhibitor; drug resistance.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Takashita E, Kawakami C, Morita H, Ogawa R, Fujisaki S, Shirakura M, et al. On Behalf Of The Influenza Virus Surveillance Group Of Japan Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018. Euro Surveill. 2019;24(3). 10.2807/1560-7917.ES.2019.24.3.1800698 - DOI - PMC - PubMed
    1. Omoto S, Speranzini V, Hashimoto T, Noshi T, Yamaguchi H, Kawai M, et al. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci Rep. 2018;8(1):9633. 10.1038/s41598-018-27890-4 - DOI - PMC - PubMed
    1. Takashita E, Morita H, Ogawa R, Nakamura K, Fujisaki S, Shirakura M, et al. Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil. Front Microbiol. 2018;9(3026):3026. 10.3389/fmicb.2018.03026 - DOI - PMC - PubMed
    1. Gubareva LV, Mishin VP, Patel MC, Chesnokov A, Nguyen HT, De La Cruz J, et al. Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons. Euro Surveill. 2019;24(3). 10.2807/1560-7917.ES.2019.24.3.1800666 - DOI - PMC - PubMed
    1. World Health Organization Meetings of the WHO working group on surveillance of influenza antiviral susceptibility – Geneva, November 2011 and June 2012. Wkly Epidemiol Rec. 2012;87(39):369-74. - PubMed

MeSH terms